On April 4, 2023, AsymBio held its 2023 annual meeting in a combination of both online and offline formats. The meeting reaffirmed and conveyed the development strategies and plans for AsymBio in 2023. The company will rally around the guideline of "Technology-Driven, Market Expansion, Compliance-Focused, Delivery-First, Cost Reduction, and Efficiency Improvement" to drive high-quality, efficient, and high-standard development. Ms. Rui Yang, Co-CEO of Asymchem Group and CEO of AsymBio, Mr. Yingwei Jiang, Executive Vice President of Asymchem Group, Dr. Kai Gao, Vice President and CTO of AsymBio, and other top executives attended the meeting, along with all employees of AsymBio.
Ms. Rui Yang, Co-CEO of Asymchem Group and CEO of AsymBio, outlined specific plans and requirements for AsymBio's development in 2023. She integrated the development plans of AsymBio into an overall analysis and consideration of industry and group development. She emphasized the importance of adhering to the "Technology-Driven, Market Expansion, Compliance-Focused, Delivery-First, Cost Reduction, and Efficiency Improvement" management guideline under the group's "Dual-Drive" strategy. The long-term development goal is to firmly establish the principles of "Technology-Driven, Customized Service, Excellent Quality, Outstanding Efficiency, and Global Leadership." The focus will be on building and enhancing the core competitiveness of the GXP one-stop service platform for conjugated drugs, efficiently empowering customers, and ensuring the successful implementation of the group's "Dual-Drive" strategy at the AsymBio level.
Dr. Kai Gao, Vice President and CTO of AsymBio, presented specific requirements for the company's work in 2023. He stressed the importance of embracing the group's technology-driven culture, emphasizing internal technology projects, showcasing excellent R&D case studies, and increasing the industry's influence. The goal is to drive continuous technological advancements and empower project execution. He also emphasized the need to implement a comprehensive market expansion strategy, both in the front and back ends, by further expanding domestic and international markets. The management requirement of "Delivery-First" will be implemented by focusing on R&D, production, analysis, and other aspects. Dr. Gao also highlighted the need to improve compliance system construction and the daily management of compliance audits, reduce the proportion of raw materials to income, refine internal workflows, and establish cross-departmental collaboration mechanisms to achieve lean management in operational support.
Mr. Yingwei Jiang, Executive Vice President of Asymchem Group, Ms. Ting Zhang, Executive Vice President of Asymchem Group, Mr. Ye Shi, Executive Vice President of Asymchem Group, and Mr. Jie Tian, Vice President of AsymBio, provided insights into development planning from the perspectives of human resources management, operational management systems, quality systems, and organizational capacity building for 2023. In 2023, all departments of AsymBio will focus on the management guideline, leveraging the mature management model and advanced experience accumulated by Asymchem Group over more than two decades. The emphasis will be on technology-driven efforts, continuous improvement of service efficiency, optimization of the quality system, and lean management in operational support. These efforts aim to drive the company to new heights.
In conclusion, Ms. Rui Yang and Dr. Kai Gao delivered their closing remarks at the meeting. They emphasized that 2023 is the year when AsymBio will fully exert its efforts. Under the guidance of the group's "Dual-Drive" strategy, all employees of AsymBio should focus on the management guideline, unite with determination, work together, and strive for excellence. They should harness their collective energy to continuously reach new heights, create new prospects, and achieve breakthrough development.
Strength arises from unity; wisdom guides our actions. The past year marked AsymBio's foundational year, and together with all employees' concerted efforts, it achieved remarkable results by serving 48 projects. Long-term corporate development relies on sound strategic judgment and exceptional strategic determination. Through top-level planning and communication at this meeting, precise planning for AsymBio's development direction and goals in 2023 was established. In the future, AsymBio will stand at a new starting point, achieve comprehensive enhancements in operational support, organizational development, quality systems, and business capabilities, serve more innovative biopharmaceutical companies, and better empower and accelerate the research and development transformation of innovative drugs.